Oncogenic pathway landscape of ovarian cancer and correlation with clinical prognosis
Journal of Gynecologic Oncology · 2025
DOI: 10.3802/jgo.2025.36.e128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2025. Verfasst von Young-Jae Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea. Hauptthemen laut MEDLINE: Ovarian Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
OBJECTIVE: We aimed to identify the main oncogenic pathway by histological type of ovarian cancer based on Next-generation sequencing (NGS) test and to determine the correlation with clinical prognosis. METHODS: We conducted a retrospective review of 420 patients with ovarian cancer who underwent NGS testing at Asan Medical Center from June 1, 2017, to May 31, 2021. Identified mutations were categorized into seven oncogenic pathways that are most frequently associated with ovarian cancer. RESULTS: The average number of oncogenic pathways involved in each cancer patient was 1.76 (range, 0-6). TP53 mutation was the primary oncogenic pathway in patients with high-grade serous carcinoma (HGSC) (92.8%) and carcinosarcoma (87.5%). MAP kinase signaling was the primary oncogenic pathway in low-grade serous carcinoma (58.3%) and mucinous carcinoma (54.5%). The involvement of more diverse oncogenic pathways has been identified in patients with endometrioid carcinoma and clear cell carcinoma and PI3K-AKT-mTOR signaling and SWI/SNF family pathways were the most common in both groups. The involvement of the DNA damage response pathway showed an association with better progression free survival (PFS), but not with overall survival (OS) in patients with HGSC. On the other hand, the involvement of the RTK signaling family pathway showed an association with better OS despite no association with PFS in patients with HGSC. CONCLUSION: The clinical prognosis may be improved by implementing targeted treatment tailored to the patient's genetic profile through NGS. Additional research is needed to determine whether the involvement of the RTK signaling family pathway is indeed associated with better OS and to identify the underlying reasons for this association.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea.
- Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. amcymkim@gmail.com.
ORCID-Profile: Young-Jae Lee, Na-Eun Kim, Jung-Hyun Bae, Chang-Ohk Sung, Shin-Wha Lee, Dae-Yeon Kim, Yong-Man Kim
Zitieren
APA
Lee, Y. J., Kim, N. E., Bae, J. H., Sung, C. O., Lee, S. W., Kim, D. Y., & Kim, Y. M. (2025). Oncogenic pathway landscape of ovarian cancer and correlation with clinical prognosis. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2025.36.e128
Vancouver
Lee YJ, Kim NE, Bae JH, Sung CO, Lee SW, Kim DY, et al. Oncogenic pathway landscape of ovarian cancer and correlation with clinical prognosis. Journal of Gynecologic Oncology. 2025. doi:10.3802/jgo.2025.36.e128
BibTeX
@article{Lee2025,
author = {Lee, Young-Jae and Kim, Na-Eun and Bae, Jung-Hyun and Sung, Chang-Ohk and Lee, Shin-Wha and Kim, Dae-Yeon and Kim, Yong-Man},
title = {Oncogenic pathway landscape of ovarian cancer and correlation with clinical prognosis},
journal = {Journal of Gynecologic Oncology},
year = {2025},
doi = {10.3802/jgo.2025.36.e128}
}
EUVIMED